Lv7
5000 积分 2022-08-15 加入
Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies—a comprehensive review of clinical outcomes
20天前
已完结
How I treat acute lymphoblastic leukemia in the era of immunotherapy while revisiting the myth of second remission
1个月前
已完结
The global epidemiology of acute myeloid leukaemia
1个月前
已完结
Malignancy-associated membranous nephropathy: focus on diagnosis and treatment
1个月前
已完结
Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group
1个月前
已完结
Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study
1个月前
已完结
Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma—a single-center retrospective study
1个月前
已完结
Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia
1个月前
已完结
Chronic myeloid leukaemia
1个月前
已完结
Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis
2个月前
已完结
皖公网安备34019202002308
